Alzecure förbereder sedan en länge tid en fas 2a-studie med bolagets innovativa projekt ACD856, en så kallad tropomyosin-receptor kinas-modu...
Redeye returns with an update following AlzeCure’s Q4 2025 earnings release.
Redeye comments on AlzeCure Pharma receiving orphan drug designation (ODD) from the European Medicines Agency (EMA) for its lead pain candid...
Alzecure drar i gång en avslutande fas 1-studie med ACD-856 för att dokumentera högre doser jämfört med doseringen i den senaste studien.
Redeye returns with an update following AlzeCure’s Q3 earnings release, which aligned with our expectations.
Alzecures nyemission bereder vägen för en europeisk fas 2a-studie med ACD856 på patienter med tidig Alzheimer.
Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expectations.
Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at 212%, raising net SEK55.
Redeye comments on the news that the FDA has granted ACD440 orphan drug designation (ODD) for the treatment of erythromelalgia.
Redeye comments on Alzecure announcing a rights issue of up to SEK58.
Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regarding the clinical path for ACD440 in the ...
Alzecure har på senare tid stärkt profilen för bolagets ledande projekt, ACD856, genom att visa data på substansens anti-inflammatoriska eff...
Redeye returns with an update following AlzeCure's Q1 2025 earnings release, which aligned with our expectations.
Redeye comments on the intriguing news that a newly published article in Nature highlights the potential of NeuroRestore ACD856 as a treatme...
Redeye returns with an update following Alzecure's Q4 report.
Alzecure får god draghjälp av European Innovation Council och kan fortsätta planeringen av en fas 2a-studie med det kognitionsförstärkande p...
Redeye endorses today’s news that AlzeCure has received a EUR2.
Alzecures forskare visar upp en stadig ström av nya resultat som stärker bolagets projekt.
Redeye returns with an update following Alzecure's Q3 report.
AlzeCure fortsätter att generera nya positiva data för sina projekt, vilket ökar möjligheterna när det kommer till affärsutveckling.
Redeye returns with an update following Alzecure's Q2 report and recent activities in the company.
AlzeCure Pharma fortsätter alltjämt att generera data för sina projekt har bland annat presenterat nya prekliniska resultat för NeuroRestore...
Redeye comments on the outcome of Alzecure’s rights issue, that secured some SEK39m before issue costs.
Redeye returns with a research update on Alzecure following its Q1 report and recent events in the company.
Redeye endorses today’s news that the nomination committee has proposed Jan Lundberg, Eli Lilly's and AstraZeneca's former head of research,...
Redeye comments on the news that Alzecure has announced a rights issue of up to SEK68m in total.
Fortsatt positiv utveckling under Q4 Som väntat rapporterade AlzeCure ingen omsättning under Q4 och periodens resultat uppgick till -9,8 mkr...
Redeye reviews the case of Alzecure after the Q4 report, which offered no surprises, and continues to see an interesting neurology platform ...
Redeye has a positive take on today’s news that Alzecure has advanced ACD137 as a drug candidate as part of its TrkA-NAM project and will no...
AlzeCure presenterade i Q3 positiva fas 2-resultat för ACD440 mot neuropatisk smärta.
Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q3 report.
Redeye comments on the additional data presented from the phase IIa study with ACD440 in neuropathic pain and reiterate our positive stance ...
Positiva data från fas 2-studien med ACD440 presenterades.
Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q2 report.
Redeye is intrigued by the publication released yesterday indicating an antidepressant-like activity with ACD856 in several pre-clinical mod...
AlzeCure rapporterade positiva data från fas 2a-studien i neuropatisk smärta med icke-opioiden Painless ACD440 i maj.
Redeye endorses yesterday’s news that Alzecure has presented positive phase IIa data with ACD440 in neuropathic pain.
Redeye returns with an update following the Q1 report.
Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and upcoming catalysts.
AlzeCure möts av ett ökat intresse från större läkemedelsbolag och målsättningen är att få till en utlicensering under 2023.
Redeye return with a short update following the Q4 report.
Redeye notes that Alzecure’s Q4 report presented revenues of SEK0m and net result of SEK-11m, which largely aligns with our expectations.
Redeye endorses yesterday’s news that Alzecure has chosen a candidate drug for its second project within the preventive Alzheimer’s platform...
Redeye comments on the outcome of Alzecures oversubscribed rights issue and reiterate our base case for now.
Q3 bjöd på positiva data från fas 1-studien med NeuroRestore.
Redeye comments on Alzecure’s Q3 report, which came in as expected.
Redeye endorses the new preclinical data presented by Alzecure at IASP, indicating an analgesic and anti-inflammatory effect with its precli...
Q2 rapporten visade positiv utveckling bland samtliga projekt och bolaget har inlett sin första fas 2a-studie vilket härleder ett högre moti...
Redeye is interested to learn more about today’s news from Alzecure.
Redeye endorses today’s news that Alzecure will present an abstract in October, which indicates (from pre-clinical research) that its lead c...
Redeye comments on today’s Q2 report from Alzecure and reiterate our view of the company.
Redeye gives a short comment on the ACD856 Phase I “MAD” data presented at the AAIC conference and reiterate our positive view of the drug c...
Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 and slightly raise our base case.
AlzeCure Pharma meddelade igår att den första patienten har inkluderats i en klinisk fas 2-studie med ACD440, den ledande icke-opioida läkem...
Redeye is positive to the recent progress with neuropathic pain candidate ACD440 and provides a short comment.
Redeye revisits its view of Alzecure in the wake of the company’s pipeline progress and recent rights issue.
AlzeCure har haft ett händelserikt nyhetsflöde. Däribland har bolaget erhållit godkännande att starta en fas 2a-studie med ACD440 samt redov...
With fresh funding in place and the FDA’s response to a pre-IND application, AlzeCure is evolving into a Phase II company with the initiatio...
Yesterday evening, Alzecure announced that it had raised in total SEK 48.
Earlier today, Alzecure announced that it had received indicative data on blood-brain-barrier penetration – that a high enough concentration...
Redeye comments on Alzecure's Q4 report and summarize our view of the year.
Redeye comments on the announced rights issue in Alzecure.
Earlier today, Alzecure reported that the company had received a supportive response from the FDA regarding its pre-IND application for its ...
AlzeCure påbörjade i oktober behandlingen av den första patienten i fas 1a-MAD-studien med NeuroRestore® ACD856 där resultat väntas under Q1...
AlzeCure gives a presentation on Alzheimer’s disease, their project platform NeuroRestore and the progress made within the program, followed...
AlzeCure has provided an update on the Phase I trial for ACD856, reporting that some promising data were observed during the initial single ...
We give a brief comment on today's news that Alzecure has recieved approval to start the "MAD"-part of its phase 1 study for ACD856.
We give a brief comment on today's news from Alzecure's ACD856 Phase I study.
Redeye gives its first impression on Alzecure’s Q2’21 report.
AlzeCures forskning valideras genom att FDA godkänner ett läkemedel med samma inriktning.
